Earnings Call Summary | Pulse Biosciences(PLSE.US) Q2 2024 Earnings Conference
Earnings Call Summary | Pulse Biosciences(PLSE.US) Q2 2024 Earnings Conference
The following is a summary of the Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript:
以下是Pulse Biosciences Inc.（PLSE）2024年第二季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Pulse Biosciences reported cash and cash equivalents totaling $26.2 million as of June 30, 2024, compared to $58.7 million the previous year.
The company noted a total GAAP cost increase of $1.5 million to $11.7 million for Q2 2024, primarily driven by non-cash stock-based compensation.
Received $60 million in gross proceeds from a rights offering which closed in July 2024, not included in the reported cash balance.
Pulse Biosciences报告称，截至2024年6月30日，现金及现金等价物总额为2620万美元，而去年同期为5,870万美元。
该公司指出，2024年第二季度的GAAP总成本增加了150万美元，至1170万美元，这主要是由非现金股票薪酬推动的。
从2024年7月结束的供股中获得了6000万美元的总收益，未包含在报告的现金余额中。
Business Progress:
业务进展：
Completed first US soft tissue ablation cases under FDA clearance and received breakthrough device designation for a cardiac surgical system.
Expanded leadership team and moved headquarters to Miami, Florida.
Plans to initiate pivotal clinical trials for soft tissue ablation and a surgical system for atrial fibrillation in early 2025.
在 FDA 批准下完成了首例美国软组织消融病例，并获得了心脏外科系统的突破性设备认证。
扩大了领导团队并将总部迁至佛罗里达州迈阿密。
计划在2025年初启动软组织消融和心房颤手术系统的关键临床试验。
More details: Pulse Biosciences IR
更多详情：Pulse Biosciences 投资者关系
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。